British Business Bank

The British Business Bank received an additional £6.6bn mandate from April 2026, authorising it for the first time to lead venture rounds and invest directly in startups at up to £60m per company. A new £4bn Industrial Strategy Growth Capital Initiative targets eight priority sectors. In the six weeks following the mandate activation, the Bank deployed capital across four direct deals: £40m cornerstone into Quantum Motion's £160m Series C (the Bank's largest single direct cheque); £13m into Elliptic's $120m Series D via both its British Growth Partnership Fund I and the core balance sheet (the first dual-instrument BBB deployment in a single deal); £12m into Cytospire Therapeutics' oversubscribed Series A; and an anchor LP position in Lansdowne Partners' €128.9m first close for a university-spinout fund targeting healthcare data, quantum, advanced materials, semiconductors and defence. The Bank also marked the two-year milestone of the Northern Powerhouse Investment Fund II with £275m deployed across 449 deals, of which £151.3m was direct BBB capital alongside £122.6m from private co-investors — a 44% private leverage ratio.

The British Business Bank was established in 2014 as a government-owned development bank to address gaps in business finance that commercial banks leave unserved. Over its first decade it became the UK's largest domestic investor in venture capital funds, supporting more than 200,000 businesses and deploying £6.3bn of public funding alongside £10bn in lending guarantees. Its historic role was as a limited partner in VC funds rather than a direct investor; the April 2026 reforms fundamentally changed this model.

The Bank's direct-investment cadence is now the clearest empirical signal of where the UK Government considers strategic capital deployment most urgent: Quantum computing (Quantum Motion), crypto compliance infrastructure (Elliptic), oncology biotech (Cytospire), and deep-tech spinout fund formation (Lansdowne). The timing is deliberate: the Bank's expansion was designed to prevent high-growth UK scale-ups from relocating to the US to access growth capital, and to provide the large, patient cheque sizes previously available only from US growth equity funds. It operates alongside the Sovereign AI Unit as part of a coordinated public capital stack.